PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Petros Grivas, MD, PhD - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All
Go online to PeerView.com/TCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients who have severe asthma with uncontrolled symptoms and exacerbations are at risk of losing lung function over time. Research and treatment over the past several years have focused on the downstream effectors of allergic and eosinophilic inflammation, including IgE, sputum and blood eosinophils, and IL-4, IL-5, and IL-13. However, the immunology of the epithelial alarmin TSLP provides an opportunity for a novel approach to treat asthma inflammation. In this activity, based on a recent live symposium, experts apply evidence-based guidelines and translate new data to treat their patients with severe asthma effectively, with a goal of reducing and preventing disease progression (eg, airway remodeling) and preserving quality of life. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting the airway epithelium in the treatment of severe, uncontrolled asthma; Apply recent pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe, uncontrolled asthma; and Select individualized treatment for patients with severe, uncontrolled asthma based on various factors, including the latest clinical evidence, without dependency on biomarker status